Solos Endoscopy Announces the MammoView(R) Breast Cancer Global Initiative for 2014
November 07 2013 - 09:51AM
Marketwired
Solos Endoscopy Announces the MammoView(R) Breast Cancer Global
Initiative for 2014
BOSTON, MA--(Marketwired - Nov 7, 2013) - Solos Endoscopy,
Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView®
Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to
work with various breast cancer awareness campaigns year round to
continue building upon the public's "brand awareness" for breast
cancer; its detection, its treatment, and the need for a reliable,
permanent cure.
Increased awareness has resulted in more women receiving
mammograms, the number of breast cancers detected, and the number
of women receiving biopsies. Solos Endoscopy believes that as a
result of awareness, breast cancers are being detected at an
earlier, more treatable stage. Awareness efforts have successfully
utilized marketing approaches to reduce the stigma associated with
the disease.
However, more work needs to be done. As part of the new
MammoView® Breast Cancer Global Initiative, Solos Endoscopy plans
to team up with the various charities and foundations who are
promoting "Breast Cancer Awareness" and educate them about the
clinical benefits of the MammoView® instrument line and breast
ductoscopy. The Solos Endoscopy MammoView® Breast Endoscopy System
can offer women a positive prognosis for recovery by detecting
breast cancer up to six times faster than conventional methods. The
MammoView® instrument line allows physicians to distinguish and
inspect suspicious pre-cancerous lesions undetectable by other
methods.
"The MammoView® Breast Cancer
Global Initiative is more than just awareness, it's about
education, and choices for women. October is over; people and
businesses nationwide will take down their pink ribbons and pink
signs, yet women all over the world will still be battling breast
cancer. Solos Endoscopy will continue its efforts to fight
breast cancer not just in October but throughout the year," stated
Robert Segersten, President of Solos Endoscopy.
Solos Endoscopy instruments
are FDA approved. Solos Endoscopy intends to place the CE Mark on
its entire MammoView® instrument line with proper approval which
will allow the instrument line to be sold globally starting in
2014.
About Solos Endoscopy, Inc.:
Solos Endoscopy celebrated its
25th Year of providing quality innovative healthcare instruments to
Hospitals across the Country. For more than 25 Years, from medical
schools to hospitals, surgeons have trusted Solos Endoscopy to
develop and market breakthrough technology, applications, medical
devices, and procedural techniques for the screening, diagnosis,
treatment and management of disease and medical
conditions. Additional information on its FDA approved
products is available on the Company's website at:
www.solosendoscopy.com.
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications that may arise could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The company cautions that these forward-looking statements
are further qualified by other factors including, but not limited
to, those set forth in the company's Annual Report filing and other
filings with the OTC Markets Group (available at
www.otcmarkets.com). The company undertakes no obligation to
publicly update or revise any statements in this release, whether
as a result of new information, future events, or otherwise.
Solos Endoscopy, Inc. Investor Relations (617) 360-9719